Nicolas H Thurin1, Magali Rouyer2, Marine Gross-Goupil3, Xavier Rebillard4, Michel Soulié5, Thibaud Haaser6, Mathieu Roumiguié5, Sylvestre Le Moulec7, Camille Capone8, Marie Pierrès8, Stéphanie Lamarque2, Jérémy Jové2, Emmanuelle Bignon2, Cécile Droz-Perroteau2, Nicholas Moore2, Patrick Blin2. 1. Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France. Electronic address: nicolas.thurin@u-bordeaux.fr. 2. Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France. 3. Department of Medical Oncology, Hôpital Saint André, CHU de Bordeaux, 1 rue Jean Burguet, 33075, Bordeaux, France. 4. Department of Urology, Clinique Beau Soleil, 119 Avenue de Lodeve, 34070, Montpellier, France. 5. Department of Urology, University Hospital of Rangueil, CHU de Toulouse, 9 Place Lange, 31059, Toulouse, France. 6. Department of Radiotherapy, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue Magellan, 33600, Pessac, France. 7. Department of Oncology, Clinique Marzet, 40 Boulevard d'Alsace, 64000, Pau, France. 8. Janssen, 1 rue Camille Desmoulins, 92130, Issy-les-Moulineaux, France.
Abstract
BACKGROUND: There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French nationwide healthcare database (SNDS). METHODS: Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Population (2013 edition). RESULTS: Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 2014. Less than one mCRPC case per 100 000 was observed in men aged 40-49. Maximum mCRPC incidence was in men aged 80-89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % negative predictive values. CONCLUSION: The good performances of the algorithm for mCRPC identification and the consistency of the generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life data will serve for future follow-up of the impact of changes in the management of prostate cancer.
BACKGROUND: There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French nationwide healthcare database (SNDS). METHODS: Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Population (2013 edition). RESULTS: Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 2014. Less than one mCRPC case per 100 000 was observed in men aged 40-49. Maximum mCRPC incidence was in men aged 80-89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % negative predictive values. CONCLUSION: The good performances of the algorithm for mCRPC identification and the consistency of the generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life data will serve for future follow-up of the impact of changes in the management of prostate cancer.
Authors: Nicolas H Thurin; Pauline Bosco-Levy; Patrick Blin; Magali Rouyer; Jérémy Jové; Stéphanie Lamarque; Séverine Lignot; Régis Lassalle; Abdelilah Abouelfath; Emmanuelle Bignon; Pauline Diez; Marine Gross-Goupil; Michel Soulié; Mathieu Roumiguié; Sylvestre Le Moulec; Marc Debouverie; Bruno Brochet; Francis Guillemin; Céline Louapre; Elisabeth Maillart; Olivier Heinzlef; Nicholas Moore; Cécile Droz-Perroteau Journal: BMC Med Res Methodol Date: 2021-05-01 Impact factor: 4.615